People with migraine and two years treatment with anti-CGRP therapies. Second report from the prospective national registry “HERCULES”

Aimovig (erenumab-aooe) - Amgen

Vyepti (eptinezumab-jjmr) - Teva, Lundbeck

Emgality (galcanezumab-gnlm) - Eli Lilly, Daiichi Sankyo

Ajovy (fremanezumab-vfrm) - Teva

Nurtec ODT (rimegepant ODT) - Pfizer

https://onlinelibrary.wiley.com/doi/10.1111/ene.70629

D. Mitsikostas 1; C. Deligianni1 2; E. Giannouli 3; E. Kouremenos 4; I. Spanou 4; T. Constantinidis 5; T. Sagona 6; E. Chroni 6; Z. Tsouris 7; E. Dardiotis 7; C. Tsironis 8; S. Konitsiotis 8

Jun 12, 2026